TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01318655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: Tablet, Oral, Once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, Oral, Once daily
Study: NCT00788294

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tanezumab
Description: Drug solution given subcutaneously only once at dose of 19 mg.
Study: NCT00678041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Description: nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
Study: NCT00643565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Description: As prescribed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy
Description: As prescribed
Study: NCT03974932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: NSAID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: NSAID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: NSAID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: +/- Bupivacaine HCl
Description: Local anesthetic.
Study: NCT00643565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5 mg/kg iv on day 1 of 9 x 3-week cycles, followed by 5 mg/kg iv on days 1 and 15 of each 4-week cycle
Study: NCT00102518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: 2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses
Study: NCT03816514

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SpHb monitoring
Description: Noninvasive, continuous pulse oximetry-based hemoglobin (SpHb) monitoring

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional management
Description: Conventional management without SpHb monitoring
Study: NCT03111914

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dual Energy Computed Tomography
Description: The subject's diagnostic scan will be preceded by a not clinically indicated non enhanced dual energy scan. The overall radiation dose to the patient for the first and second acquisition will be twice the radiation dose of a conventional CT of the chest, abdomen and pelvis. The non enhanced dual energy scan will be repeated during a clinical follow-up after the subject's first three months of enrollment and at a clinical follow-up after six months of enrollment.~The clinically-indicated, contrast-enhanced diagnostic scan will be performed according to standard of care.
Study: NCT02569112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multipolar RF, varipulse
Description: Multi-polar Radio frequency (RF) technology combining pulsed electro magnetic fields (PEMF) and mild suction stimulation (varipulse).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryolipolysis
Description: Cryolipolysis technology uses the sensitivity of fat cells to cold injury, causing them to freeze and undergo cellular apoptosis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryolipolysis
Description: Cryolipolysis technology uses the sensitivity of fat cells to cold injury, causing them to freeze and undergo cellular apoptosis.
Study: NCT01592305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir
Description: multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir
Description: multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: multiple oral doses
Study: NCT00106080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: Intervention patients and clinicians received a one-page patient-specific individualized summary, based on questionnaire responses, to stimulate conversations.
Study: NCT01592305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil fumarate
Description: single oral doses
Study: NCT03584984

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)
Description: Filling the socket with Mixing of autogenous bone graft and anorganic bovine bone in a 50:50 ratio

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anorganic Bovine Bone (ABB)
Description: Filling the socket with Anorganic bovine bone graft material only
Study: NCT03974932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer Lock Applicator
Description: Applicator for instillation.
Study: NCT02861066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Description: MBI will be delivered in group format, 120 minutes per week, for 6 consecutive weeks with 10-20 participants per group.
Study: NCT04034771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 10 MG Oral Tablet
Description: Melatonin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: propofol amp

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol amp

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: sugar pill manufactured to mimic melatonin tablets
Study: NCT05035966

Intervention type: OTHER
Intervention: Plasma β-amyloid 40 and 42 concentration
Description: Plasma β-amyloid 40 and 42 concentrations were simultaneously measured by validated assay platforms from Meso Scale Discovery (MSD; Rockville, MD, USA).

Intervention type: OTHER
Intervention: Plasma β-amyloid 40 and 42 concentration
Description: Plasma β-amyloid 40 and 42 concentrations were simultaneously measured by validated assay platforms from Meso Scale Discovery (MSD; Rockville, MD, USA).
Study: NCT04457752

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dual Layer Amniotic Membrane (DLAM). Artacent®
Description: Artacent® is a double layer of dehydrated amniotic membrane. The amnion is harvested from human placenta obtained during planned Caesarean sections. Tides Medical uses a proprietary process to clean and decellularize the amniotic membrane. The amnion is then folded into a bi-layer with the stromal sides facing outward. The dual layer is dried and cut into various sizes. In the final step the DLAM is terminally sterilized.~Atracent®, like all other placental-derived products, is FDA cleared for homologous use through the 361 pathway. It is indicated for non-healing ulcers applied to a debrided, clean and uninfected ulcers.
Study: NCT05025995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious health game
Description: Serious health game

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious health game
Description: Serious health game
Study: NCT02330926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutritional supplements and advice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home-based self-assisted exercise program

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Study: NCT01248260

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 4mg of higher strength folic acid once a day until delivery
Study: NCT01448317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab (Solution)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab (Lyophilized formulation)
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab (Lyophilized formulation)
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab (Lyophilized formulation)
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Solution)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Lyophilized formulation)
Description: Pharmaceutical form: lyophilized formulation~Route of administration: Subcutaneous
Study: NCT00603850

Intervention type: DEVICE
Intervention: ForeseeHome
Description: human factor
Study: NCT01056419

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Thyroidectomy
Description: Total thyroidectomy within 6 months after the appearance of the symptoms of ophthalmopathy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propylthiouracil
Description: 150-600 mg in two-three divided doses
Study: NCT02509676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercise
Description: dynamic stretching exercises with 5 repetitions, each lasting 45 seconds, for 5 days a week and 3 times a day
Study: NCT05007223

Intervention type: DRUG
Intervention: Doxycycline
Description: 200mg/day for 28 days(Given doxycycline to patients with Hailey-Hailey disease)
Study: NCT03446989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management
Description: completing assessment, detecting the presence of RA complications, consultation about taking medications and exercise, education for patients and their family, assist in formulating a management, and providing a basis for continuing care for each patient. Additionally, the management plan was rationally modified in accordance with the individualized therapeutic alliance of the patient, his/her family, the physician or other members of the medical team.
Study: NCT02573337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emervel Classic Lidocaine
Description: Treatment of wrinkles and folds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emervel Deep Lidocaine
Description: Treatment of wrinkles and folds
Study: NCT00050622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate 0.15 mg/kg
Description: 0.15 m/kg/dose immediate-release methylphenidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate 0.15 mg/kg
Description: 0.15 m/kg/dose immediate-release methylphenidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate 0.15 mg/kg
Description: 0.15 m/kg/dose immediate-release methylphenidate

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity BMOD
Description: Lower-intensity behavioral treatment package.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity BMOD
Description: Lower-intensity behavioral treatment package.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity BMOD
Description: Lower-intensity behavioral treatment package.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity BMOD
Description: Lower-intensity behavioral treatment package.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate 0.3 mg/kg
Description: 0.3 mg/kg/dose immediate-release methylphenidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate 0.3 mg/kg
Description: 0.3 mg/kg/dose immediate-release methylphenidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate 0.3 mg/kg
Description: 0.3 mg/kg/dose immediate-release methylphenidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate 0.6 mg/kg
Description: 0.3 mg/kg/dose immediate-release methylphenidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate 0.6 mg/kg
Description: 0.3 mg/kg/dose immediate-release methylphenidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate 0.6 mg/kg
Description: 0.3 mg/kg/dose immediate-release methylphenidate

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity BMOD
Description: Comprehensive high-intensity Summer Treatment Program (STP)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity BMOD
Description: Comprehensive high-intensity Summer Treatment Program (STP)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity BMOD
Description: Comprehensive high-intensity Summer Treatment Program (STP)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity BMOD
Description: Comprehensive high-intensity Summer Treatment Program (STP)
Study: NCT03483116

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV3-BB
Description: Oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV3-BB
Description: Oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV3-BB
Description: Oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV3-BB
Description: Oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration
Study: NCT01577784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg / day of pazopanib in monotherapy.
Study: NCT01592006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Patients will be treated with pegylated interferon alfa-2a (Pegasys®) 180 mcg SQ per week for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Patients will be given ribavirin 600-1200 mg PO per day for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Patients will be given telaprevir 750 mg tid (Incivek®) for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
Study: NCT04348994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-ablative thermal-only Er:YAG laser therapy
Description: Each patient will receive 3 sessions of Er:YAG laser treatment for SUI (IncontiLase®).~Single-session treatments will be offered to patients after 18, 24 and 30 months following the initial three sessions.
Study: NCT02789826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: Patients allocated to the 'laparoscopic gastrectomy' arm will receive gastrectomy via laparoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Description: patients allocated to the 'Open gastrectomy' group will receive gastrectomy via laparotomy
Study: NCT04355026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromhexine Oral Tablet and/or hydroxychloroquine tablet
Description: bromhexine 16 mg TID hydroxychloroquine 200 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine Oral Tablet and/or hydroxychloroquine tablet
Description: bromhexine 16 mg TID hydroxychloroquine 200 mg BID
Study: NCT02157103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 25 mg in 1 ml subcutaneously daily
Description: Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.
Study: NCT03000686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2586881
Description: GSK2586881 will be a clear colorless liquid for IV infusion over 3- 5 mins and will be administered as unit dose 0.8 mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2586881
Description: GSK2586881 will be a clear colorless liquid for IV infusion over 3- 5 mins and will be administered as unit dose 0.8 mg/kg.
Study: NCT03584984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable gelatin sponge
Description: Filling the socket with an absorbable gelatin sponge foam pack
Study: NCT02958423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial DCS Healthy Volunteers
Description: The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of healthy volunteers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transspinal DCS Healthy Volunteers
Description: The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of healthy volunteers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial DCS CPP patients
Description: The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of CPP patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transspinal DCS CPP patients
Description: The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of CPP patients
Study: NCT03000686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline (0.9%) will be administered as a single IV dose infusion over 3 to 5 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline (0.9%) will be administered as a single IV dose infusion over 3 to 5 min.
Study: NCT01785108

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GAD-Alum (Diamyd) 20 µg
Study: NCT03468335

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan Liposomal Injection [Onivyde]
Description: Cancer treatment for PDAC:~* Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion~* 5-FU 2400 mg/m2 as 46 hour infusion~* Folinic acid 400 mg/m2 as 0.5 hour infusion~* all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent.
Study: NCT02796118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral
Study: NCT01785108

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GAD-Alum (Diamyd) 20 µg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GAD-Alum (Diamyd) 20 µg X 2

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GAD-Alum (Diamyd) 20 µg X 2
Study: NCT02796118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT03705130

Intervention type: DEVICE
Intervention: Single Vision Contact Lens
Description: Spherical Contact Lens worn on non-dispensing basis

Intervention type: DEVICE
Intervention: Multifocal Contact Lens 1
Description: Multifocal Contact Lens worn on non-dispensing basis

Intervention type: DEVICE
Intervention: Multifocal Contact Lens 2
Description: Multifocal Contact Lens worn on non-dispensing basis
Study: NCT01448317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Lyophilized formulation)
Description: Pharmaceutical form: lyophilized formulation~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Lyophilized formulation)
Description: Pharmaceutical form: lyophilized formulation~Route of administration: Subcutaneous
Study: NCT02825641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Description: Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes.
Study: NCT05376436

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise challenge test (ECT)
Description: Baseline demographic, clinical and rest lung functions were recorded. ECT was performed on treadmill according to fixed protocol. Clinical data during ECT was recorded. (visit 1- performed with nose clip, visit 2- performed without nose clip). Lung function were measured and recorded at fixed time after ECT and after bronchodilator administration.